- Canadian clinical-stage drug development company InMed Pharmaceuticals is working to achieve pharmaceutical approval of rare cannabinoids
- InMed Pharmaceutical has developed a trademarked platform called IntegraSyn that extracts five times the normally expected yields of cannabinoids from its plant sources
- IntegraSyn’s ability to increase yields may ultimately help InMed to achieve a profitable means of producing cannabinol (“CBN”) and other lesser-known cannabinoids at commercial scales
- To date, GW Pharma’s Epidiolex is the only cannabis-derived product to achieve FDA approval as a pharmaceutical, and the company’s multi-million-dollar revenues demonstrate the potential returns a pharmaceutical-level drug can achieve
British Columbia, Canada-based InMed Pharmaceuticals (NASDAQ: INM) is developing a proprietary cannabinoid synthesis manufacturing system known as IntegraSyn with a goal of advancing its rare and lesser-known cannabinoid production to commercial levels.
“The next key milestone is to manufacture our first large-scale batch through a pharma-grade-ready process in the coming months. We will continue to optimize the process and scale up the IntegraSyn(TM) process into larger vessels,” InMed Pharmaceuticals CEO Eric A. Adams stated in a recent Vista Partners interview (https://ibn.fm/2fQhd).
“Considering our production methodology is being designed with the flexibility to produce multiple cannabinoids, it opens up many different markets and consumer categories,” Adams added. “We continue to develop relationships with contract manufacturing organizations for scale-up of the process with the anticipation of commercializing the process shortly. Our immediate commercial plans are to become a B2B wholesale supplier of rare cannabinoids to companies that are seeking to integrate rare cannabinoids into their marketed products.”
IntegraSyn targets the manufacture of pharmaceutical-grade cannabinoids rather than the market for recreational use products, which includes an effort to create a commercial pipeline for cannabinoid-based medications that target diseases with high unmet medical needs.
The company’s initial focus is on the therapeutic benefits of cannabinol (“CBN”), a mildly psychoactive cannabis component derived from tetrahydrocannabinolic acid (“THC-A”) that can be used to relieve pain and inflammation stemming from conditions such as arthritis and Crohn’s disease (https://ibn.fm/kRNZ0).
“Beyond the well-known cannabinoids of THC and CBD, there’s a whole world of rare cannabinoids including CBG, CBN, CBC and THCV with unique properties that are believed to have a wide range of health benefits. These minor or rare cannabinoids are present in much smaller quantities in the plant and therefore have not been studied extensively due to limited access,” Adams stated. “Achieving a (high) yield of 5g/L (with IntegraSyn) means we were able to make 5 times more cannabinoid product using the same process in the same amount of time, thus substantially lowering overall manufacturing costs. Achieving a yield of 5g/L significantly exceeds any currently reported industry yields, making InMed one of the leaders within the industry.”
InMed Pharmaceuticals anticipates further increasing the cannabinoid yield as achieved with IntegraSyn and supplying companies that intend to market finished products with economies of scale that further reduce overall manufacturing costs.
By their nature, pharmaceutical-grade products are the most expensive because of the greater efforts required to establish production process controls, validate the production system and ultimately offer final assurances of the product’s sustained quality.
At this time, only one cannabis-based product has achieved FDA approval — GW Pharma’s Epidiolex was developed in 2018 as a pharmaceutical-grade oral solution containing cannabidiol (“CBD”) for the treatment of seizures associated with two rare and severe forms of epilepsy (https://ibn.fm/7Y2Ha) and last year treatment of a third disease was added to the drug’s indicated effectiveness (https://ibn.fm/YxERW).
Adams noted that GW Pharma was recently acquired by Jazz Pharmaceuticals (NASDAQ: JAZZ) for $7.2 billion and that the company’s sales exceeded $500 million during 2020 and were expected to grow to over $1 billion soon.
“What this tells us is, if you can advance one of these rare cannabinoids through the pharmaceutical development process, which is both lengthy and costly, and demonstrate both clinical efficacy and relative safety in a certain disease, it presents a significant commercial opportunity,” he said.
For more information, visit the company’s website at www.InMedPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com